Loncar Cancer Immunotherapy ETF (%)
(CNCR)| Years | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | ||||
| 2024 | 23.39 | -5 | ||
| 2023 | -12.68 | 7.77 | -15.21 | 28.04 |
| 2022 | -24.37 | -15.61 | -3.55 | -6.29 |
| 2021 | 16.95 | 4.27 | -0.73 | 8.21 |
| 2020 | -16.66 | 38.67 | 171.12 | -41.51 |
| Years | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | ||||
| 2024 | 23.39 | -5 | ||
| 2023 | -12.68 | 7.77 | -15.21 | 28.04 |
| 2022 | -24.37 | -15.61 | -3.55 | -6.29 |
| 2021 | 16.95 | 4.27 | -0.73 | 8.21 |
| 2020 | -16.66 | 38.67 | 171.12 | -41.51 |